Archives

In silico prediction of an optimum dosimetric combination of DMSO, carboxylated ε-poly-L-lysine cryoprotectant agents with minimum Thermal Conductivity Differences between the Crystalline and Vitrified States with Applications to Cryopreservation on Efficient production of live autologous cartilage derived chondrocytes vitrified with optical properties of water soluble CdSeS nanocrystals using glycerin as terminal stabilizing agent

Abstract

Thermal conductivity of dimethyl-sulfoxide (DMSO) solution is measured in this study using a transient hot wire technique, where DMSO is a key ingredient in many cryoprotective agent (CPA) cocktails. Characterization of thermal properties of cryoprotective agents is essential to the analysis of cryopreservation processes, either when evaluating experimental data or for the design of new protocols. Also presented are reference measurements of thermal conductivity for pure water ice and glycerol. The thermal conductivity measurement setup is integrated into the experimentation stage of a scanning cryomacroscope apparatus, which facilitates the correlation of measured data with visualization of physical events. Thermal conductivity measurements were conducted for a DMSO concentration range of 2M and 10M, in a temperature range of -180°C and 25°C. Vitrified samples showed decreased thermal conductivity with decreasing temperature, while crystalline samples showed increased thermal conductivity with decreasing temperature. These different behaviors result in up to a tenfold difference in thermal conductivity at -180°C. Such dramatic differences can drastically impact heat transfer during cryopreservation and their quantification is therefore critical to cryobiology. Water solution of Na2SeO3 in polyethylene glycol was utilized as Se source. 3-Mercaptopropionic acid (MPA) provides S source. The phosphine-free Se and S sources were found to be highly reactive and suitable for the synthesis of CdSeS nanocrystals. XRD and HRTEM images confirm the formation of CdSeS nanocrystals in zinc blende structure. The absorption peaks on UV-vis spectra of as-prepared CdSeS nanocrystals are tunable from 330 nm to 440 nm, which blue shifts to shorter wavelength side in comparison with that of pure CdSe nanocrystals. The cubic CdSeS nanocrystals demonstrate narrow PL emissions spectra between 464 and 615 nm. Transmission electron microscopy images show the uniformity for the size distribution of the ternary QDs. Series water soluble CdSe1–xSx (x = 0∼1) nanocrystals have also been synthesized using Na2SeO3 and Na2S solution as the Se-S co-sources. Tunable band gap energies of CdSe1–xSx (x = 0∼1) nanocrystals upon chemical composition x have been achieved, the gap ranges from 290 nm to 558 nm. Herein we present an unusual phosphine-free method to fabricate water soluble CdSeS nanocrystals in cubic structure. In this method, glycerin was used as a stabilizing agent replacing tri-n-octylphosphine oxide (TOPO). In a continuing effort to develop dosimetric systems that will enable reliable interpretation of dosimeter readings in terms of the absorbed DMSO dose or dose-equivalent, a new multi-element TL dosimeter assembly for the prediction of an optimum dosimetric combination of DMSO, carboxylated ε-poly-L-lysine cryoprotectant agents with minimum Thermal Conductivity Differences between the Crystalline and Vitrified States with Applications to Cryopreservation on Efficient production of live autologous cartilage derived chondrocytes vitrified with optical properties of water soluble CdSeS nanocrystals using glycerin as terminal stabilizing agent.

An in silico axisymmetric multistage model of linear biphasic mesenchymal stem cell and chondrocyte protein secreted-matrix interactions for the reconstruction of the dynamic mechanical environment of a time varying magnetic field expanded chondrocyte biphasic finite elemental model in articular cartilage for the evaluation of the ability of natural and synthetic scaffolds in providing an appropriate environment for growth and sustain of the chondrogenic capacity of de-differentiated of cartilage-derived L-lactic glycolic acid (PLGA) loaded chondrocytes for and then for autologous transplantations

Abstract

A new optimization algorithm for combined processes of deep-drawing and ironing has been created in order to improve these types of axisymmetric components manufacturing procedures. The model provides a comprehensive analysis of those phenomena occurring in multi-stage processes of axisymmetric geometry work-pieces. The scientific development starts out from works that provide LDR (limiting drawing ratio) solutions based on normal anisotropy value, strain hardering exponent and others parameters which have just been applied to the drawing and redrawing stages so far. During embryogenesis, specific proteins expressed in cells have key roles in the formation of differentiated cells and tissues. Delivery of specific proteins into specific cells, both in vitro and in vivo, has proved to be exceedingly difficult. The PLGA NPs were used to deliver proteins into human mesenchymal stem cells (hMSCs). Fluorescent markers loaded into the PLGA NPs were used to verify the internalization of NPs into hMSCs using FACS analysis and confocal microscopy. With these methods, we demonstrated that the encapsulated model proteins are readily delivered into hMSCs, released from the NP vehicles, and, finally, moved into the cytosols. Using chondrogenesis-related proteins such as aggrecan and cartilage oligomeric matrix protein (COMP), chondrogenic differentiation of hMSCs treated with aggrecan and COMP encapsulated PLGA NPs was clearly observed and caused to differentiate into chondrocytes. The authors extend this work to the ironing stages, and also provide a global and integral scientific solution for the whole process. At the beginning the algorithm provides an initial solution which is afterwards optimized by means of objective functions and constraints. The resolution of the optimization process is carried out by a recursive function that minimizes the total time of the global process. The enhanced solution performs a significant reduction in time and costs of the process. The model allows the modification and correction of certain process variables in order to predict the impact of those that are not fully controllable. The final results are compared using experimental results obtained by the authors, so as to show the reliability of the complete solution. In this study, we developed a safe and efficient protein delivery system using An in silico axisymmetric multistage model of linear biphasic mesenchymal stem cell and chondrocyte protein secreted-matrix interactions for the reconstruction of the dynamic mechanical environment of a time varying magnetic field expanded chondrocyte biphasic finite elemental model in articular cartilage for the evaluation of the ability of natural and synthetic scaffolds in providing an appropriate environment for growth and sustain of the chondrogenic capacity of de-differentiated of cartilage-derived L-lactic glycolic acid (PLGA) loaded chondrocytes of proteins into biodegradable poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).

A Computer-Aided meta-analyses reveal Accelerated weightbearing rehabilitation and time-dependent differences between the clinical outcomes achieved by microfracture and mesenchymal stem cells induced implantation of PolyScaffolding based Matrix-induced autologous chondrocyte implantation (POMACI) for chondral defects in the patellofemoral joint after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint: early clinical and radiological outcomes

Abstract

A Computer-Aided meta-analyses reveal Accelerated weightbearing rehabilitation and time-dependent differences between the clinical outcomes achieved by microfracture and mesenchymal stem cells induced implantation of PolyScaffolding based Matrix-induced autologous chondrocyte implantation (POMACI) for chondral defects in the patellofemoral joint after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint: early clinical and radiological outcomes.

A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous Improvements of outcomes after an autologous cartilage tissue implantation, compared with microfracture for treatment of distal femoral cartilage lesions

Abstract

The dynamics of tumor burden, secreted proteins or other biomarkers over time, is often used to evaluate the effectiveness of therapy and to predict outcomes for patients. Many methods have been proposed to investigate longitudinal trends to better characterize patients and to understand disease progression. However, most approaches assume a homogeneous patient population and a uniform response trajectory over time and across patients. Simulation results show that our method was able to classify subjects according to their patterns of treatment response with greater than 80% accuracy in the three scenarios tested. We then applied our model to a large randomized controlled phase III clinical trial of multiple myeloma patients. Analysis results suggest that the longitudinal tumor burden trajectories in multiple myeloma patients are heterogeneous and nonlinear, even among patients assigned to the same treatment cohort. In addition, between cohorts, there are distinct differences in terms of the regression parameters and the distributions among categories in the mixture. The bootstrap method for estimating the standard error of the kappa statistic in the presence of clustered data is evaluated. Such data arise, for example, in assessing agreement between physicians and their patients regarding their understanding of the physician-patient interaction and discussions. We propose a computationally efficient procedure for generating correlated dichotomous responses for physicians and assigned patients for autologous cartilage tissue implantation, compared with microfracture for treatment of distal femoral cartilage lesions simulation studies. The simulation result demonstrates that the proposed bootstrap method produces better estimate of the standard error and better coverage performance compared to the asymptotic standard error estimate that ignores dependence among patients within physicians with at least a moderately large number of clusters. An example of an application to an autologous cartilage tissue implantation, compared with microfracture for treatment of distal femoral cartilage lesions prevention study is presented. Those results imply that longitudinal data from clinical trials may harbor unobserved subgroups and nonlinear relationships; accounting for both may be important for analyzing longitudinal data.Here, we present a mixture piecewise linear Bayesian hierarchical model, which takes into account both population heterogeneity and nonlinear relationships between biomarkers and time of autologous cartilage tissue implantation, compared with microfracture for treatment of distal femoral cartilage lesions.

ArthroCartiGenea®-AR: A Mesenchymal stem cells Co-Cultured Chondrocytes Comprising Chondrogenic Autologous Treatment for patients with Osteoarthritis and large Cartilage defects on assessing the Clinical Impact of Approximations in Analytical Dose Calculations for Advanced Cell Therapy

Abstract

A Therapeutic Alternative to Treat Focal Osteoarthritic Cartilage Lesions. Human mesenchymal stem cells (MSCs) are present in most of the tissue matrix, taking part in their regeneration when injury or damage occurs. The aim of this ArthroGenea®-AR was to investigate the presence of cells with pluripotential characteristics in synovial membranes from osteoarthritic (OA) patients and the capacity of these cells to differentiate to chondrocytes. Methods. Synovial membranes (n _ 8) from OA patients were digested with collagenase. Isolated cells were cultured with DMEM, 20% FBS, and FGFb10 ng/mL. Cells from second subculture were used to carry out phenotypic characterization experiments (flow cytometry analysis with 11 monoclonal antibodies) and chondrogenic differentiation experiments (micropellet cultured in chondrogenic medium). Chondrogenic differentiation of cells was assessment by quantification of cartilage extracellular matrix components by following techniques: Safranin O, Toluidine Blue, and Alcian Blue stains to detect proteoglycans and immunohistochemistry to detect type I and II collagen. Results. Flow cytometry analyses showed that in our population more than 90% of cells were positive for MSC markers: CD29 (95%), CD44 (90%), CD73 (95%), CD90 (98%). Cells were negative for hematopoietic markers (CD11b, CD34, and CD45). Furthermore, cells showed positive stain to multipotent markers such as CD117 (c-kit) (98%), CD166 (74%), and STRO-1 (88%) and to quiescent satellite cells like PAX-7 (35%). The micropellet analyses showed that the culture of these cells with TGFbeta-3 for 2 and 3 weeks stimulates proteoglycan and collagen type II synthesis. Both molecules are characteristic of hyaline articular cartilage. Conclusion. In this work, we demonstrate the presence of a cellular population with MSC characteristics in synovial tissue from OA patients.

Introduction

Osteoarthritis (OA) is characterized by an imbalance in cartilage and underlying subchondral bone homeostasis. We hypothesized that signals from the subchondral bone may modulate production of matrix components, alter chondrogenic differentiation potential of cocultured bone marrow-derived mesenchymal stem cells (BMSC) and induce a phenotypic shift in differentiated OA chondrocytes. As planning algorithms become increasingly accurate, quality assurance tests need to become more sophisticated to uncover discrepancies between reality and calculations which may only present themselves in complex geometrical situations (inhomogeneities etc.). Gel dosimetry and Monte Carlo simulations are capable of providing detailed dose information for comparison where more conventional dosimetry has limitations. In this work we aim to use both Monte Carlo calculations and polymer gel dosimetry to compare with results from a treatment planning system.

Methods

We established a novel coculture model between BMSC, mixed cultures (BMSC and chondrocytes) and chondrocytes embedded in fibrin gel with OA and normal subchondral bone explants (OAB and NB). Tissues and cells were either derived from OA or trauma patients. In addition, we used adipose-derived stem cells (ASC) from liposuction. With gene expression analysis, biochemical assays, immunofluorescence and biomechanical tests we characterized the properties of newly generated extracellular matrix (ECM) from chondrocytes and chondrogenically differentiating BMSC cocultured with OAB or NB in comparison with monocultures (cultures without bone explants). The standard method to calculate and optimize dose distributions for a patient treatment plan is based on fast analytical dose calculation (ADC) algorithms. These algorithms calculate dose along narrow width beams (pencils) with a certain spread. While more accurate dose calculation engines are available, they are not yet standard in clinical practice. The Monte Carlo (MC) simulation method is considered the gold standard to describe particle interactions and calculate the resulting dose.

Results

Our results suggest a variety of gel phantoms were constructed to test the performance of calculations in different situation such as homogeneous and inhomogeneous phantoms as an alteration of molecular composition and mechanical properties of the newly formed ECM in subchondral bone cocultures. We suggest that soluble factors, that is interleukins and bFGF, released in cocultures exert inhibitory effects on collagen and temporary effects on proteoglycan production, which finally results in a reduction of mechanical strength of newly formed fibrillar living networks of Mesenchymal stem cells Co-Cultured Chondrocytes Comprising Chondrogenic Autologous Treatment for patients with Osteoarthritis and large Cartilage defects on assessing the Clinical Impact of Approximations in Analytical Dose Calculations for Advanced Cell Therapy.

An in silico designed Fusion Inhibitor consisting of five cancer filtered conserved pharmacophoric chemical fragments with Greatly Promising Pharmaco-Mimic Properties to a Rationally Engineered Wilms’ Tumor Peptide as a future computer generated hyper-molecule for the potential treatment of the acute myeloid leukemia

Abstract

Wilms’ Tumour 1 (WT1) is a zinc finger transcription factor that is overexpressed in acute myeloid leukaemia (AML). Its restricted expression in normal tissues makes it a promising target for novel immunotherapies aiming to accentuate the cytotoxic T lymphocyte (CTL) response against AML. It has been previously reported a phase I/II clinical trial of subcutaneous peptide vaccination with two separate HLA-A2-binding peptide epitopes derived from WT1, together with a pan-DR binding peptide epitope (PADRE), in Montanide adjuvant. Here, in Biogenea we have for the first time discovered an in silico designed Fusion Inhibitor consisting of five conserved cancer-related pharmacophores with Greatly Promising PharmacoMimic Properties to a Rationally Engineered Anti-Wilms’Tiumor Peptide.

A predicted chemo-polypharmacophoric agent comprising (Propeptide-Fc)/MGF peptide mimicking interactive of high free binding energy properties towards Wnt7a/Fzd7 signalling Akt/mTOR anabolic growth IGF-I/PI3K/Akt -I/MAPK/ERK pathways

Abstract

The insulin-like growth factor-I (IGF-I) is a key regulator of skeletal muscle growth in vertebrates, promoting mitogenic and anabolic effects through the activation of the MAPK/ERK and the PI3K/Akt signaling pathways. Also, these results show that there is a time-dependent regulation of IGF-I plasma levels and its signaling pathways in muscle. The insulin-like growth factor-I (IGF-I) is a key regulatory hormone that controls growth in vertebrates. Particularly, skeletal muscle growth is strongly stimulated by this hormone. IGFI stimulates both proliferation and differentiation of myoblasts, as well as promoting myotube hypertrophy in vitro and in vivo. The mitogenic and anabolic effects of IGF-I on muscle cells are mediated through specific binding with the IGF-I receptor (IGF-IR). This ligand-receptor interaction promotes the activation of two major intracellular signaling pathways, the mitogen-activated protein kinases (MAPKs), specifically the extracellular signal-regulated kinase (ERK), and the phosphatidylinositol 3 kinase (PI3K)/Akt. The MAPK (RAF/MEK/ERK) is a key signaling pathway in skeletal muscle, where its activation is absolutely indispensable for muscle cell proliferation. Biologically active polypeptides derived from the E domain that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor which have been demonstrated neuroprotective and cardioprotective properties, as well as the ability to increase the strength of normal and dystrophic skeletal muscle. Ligands selected from phage-displayed random peptide libraries tend to be directed to biologically relevant sites on the surface of the target protein. Protein-peptide interactions form the basis of many cellular processes. Consequently, peptides derived from library screenings often modulate the target protein’s activity in vitro and in vivo and can be used as lead compounds in drug design and as alternatives to antibodies for target validation in both genomics and drug discovery. In this research and science project we for the first time a predicted chemo-polypharmacophoric agent comprising (Propeptide-Fc)/MGF peptide mimicking properties for the possible increasement of the Muscle Mass Fiber Size towards Wnt7a/Fzd7 Signalling to the Akt/mTOR Anabolic Growth IGF-I/PI3K/Akt -I/MAPK/ERK pathways utilising (Propeptide-Fc)/MGF phage-displayed random peptide libraries through a KNIME-RDkit-CDK clustering pipeline.

A mechanistic in silico molecular recognized approach for the ligand based generation of a dual N-formyl-Met-Leu-Phe (fMLP), and MMK-1peptide mimetic hyper-agonist fMLP targeted receptor against the PGE2 EP4 pathway chemotherapy-induced alopecia

Abstract

It has been shown that the Oral administration for 6 days of 100 mg/kg MMK-1, of an agonist peptide selective for the FPRL1 receptor, suppressed alopecia induced by the anticancer drug etoposide in neonatal rats. However, the anti-alopecia effect of orally administered MMK-1 was inhibited by indomethacin, an inhibitor of cyclooxygenase (COX), or AH-23848B, an antagonist of the EP4 receptor for prostaglandin (PG) E2, suggesting involvement of PGE2 release and the EP4 receptor in the oral MMK-1 anti-alopecia mechanism. The anti-alopecia effect of orally administered MMK-1 was also blocked by an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate, suggesting that the oral anti-alopecia effect of MMK-1 may be mediated by activation of NF-kappaB. These results suggested that MMK-1 bound to FPRL1 receptor might suppress etoposide-induced apoptosis of hair follicle cells and alopecia by way of PGE2 release and NF-kappaB activation. Previously, it has also been found that an intraperitoneally administered chemotactic peptide, N-formyl-Met-Leu-Phe (fMLP), and MMK-1, a selective agonist of formyl peptide receptor-like 1 (FPRL1) receptor, the low affinity subtype of the fMLP receptor, prevented the alopecia in neonatal rats induced by the anticancer agent etoposide. The anti-alopecia effect of fMLP was not inhibited at all by Boc-FLFLF, a selective antagonist of formylpeptide receptor (FPR), which is the high affinity subtype of the receptor, but it was partly inhibited by Trp-Arg-Trp-Trp-Trp-Trp-NH(2) (WRW(4)), an antagonist of FPRL1 receptor. The anti-alopecia effects of fMLP and MMK-1 were also inhibited by Lys-D-Pro-Thr (K(D)PT) and pyrrolidine dithiocarbamate, which are inhibitors of interleukin-1 (IL-1) and nuclear factor-kappaB (NF-kappaB) respectively. Computational methods utilizing the structural and functional information help to understand specific molecular recognition events between the target biomolecule and candidate hits and make it possible to design improved lead molecules for the target. Here we represents a massive on-going scientific endeavor to provide a freely accessible state of the art software suite for protein and DNA targeted lead molecule discovery. by resulting in a Mechanistic in silico molecular recognized approach for the ligand based generation of a dual N-formyl-Met-Leu-Phe (fMLP), and MMK-1peptide mimetic agonists formyl-peptide hyper-agonist interactive receptors against chemotherapy-induced alopecia.

A rational in silico drug-target flexibility complement methodology-design for the generation of a peptide-mimic novel pharmacoelement binding to the amino acid conserved sequences of the active loop of a Haemophilus influenzae porin P2

Abstract

Haemophilus influenzae type b (Hib) is one of the leading causes of invasive bacterial infection in young children. It is characterized by inflammation that is mainly mediated by cytokines and chemokines. One of the most abundant components of the Hib outer membrane is the P2 porin, which has been shown to induce the release of several inflammatory cytokines. A synthetic peptide corresponding to loop L7 of the porin activates JNK and p38 mitogen-activated protein kinase (MAPK) pathways. It has also been reported that a novel use of the complementary peptide approach to design a peptide that is able to bind selectively to the protein P2, thereby reducing its activity. Insights have also been provided into that essential molecular details of P2 that may affect the pathogenesis of Hib infections where interruption of the signaling cascade could represent an attractive therapeutic strategy.. Here, in Biogenea Pharmaceuticals Ltd we discovered for the first time the GENEA-Poriflunzaten-5567 a Peptide-mimic novel pharmacoelements complementary to the active loop of porin P2 from Haemophilus influenzae for the annotated modulation of its activity using Molecular simulation methods in drug discovery process: a BiogenetoligandorolTM prospective.

A Computer-aided rational approach for the in silico generation of a TCR Peptide Mimetic Pharmacoligand as a potential chemo-modulator in Human Autoimmune Diseases

Abstract

Inflammatory Th1 cells reacting to tissue/myelin derived antigens likely contribute to the pathogenesis of diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. One regulatory mechanism that may be useful for treating autoimmune diseases involves an innate second set of Th2 cells specific for portions of the T cell receptor of clonally expanded pathogenic Th1 cells. These Th2 cells are programmed to respond to internally modified V region peptides from the T cell receptor (TCR) that are expressed on the Th1 cell surface in association with major histocompatibility molecules. TB Mobile can now manage a small collection of compounds that can be imported from external sources, or exported by various means such as email or app-to-app inter-process communication. This means that TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also cluster compounds and use internal algorithms to help identify potential targets based on. Here, in Biogenea we have for the first time discovered a a TCR Peptide comprising potential Therapy Mimetic Pharmacophoric activation in Human Autoimmune Diseases by using BiogenetoligandorolTM and a New target prediction and visualization drug discovery tools.